Advertisement
CABA vs NCEL
Which Stock Would AI Choose? Cabaletta Bio (CABA) vs. NewcelX (NCEL) Stock Comparison
Key Takeaways
- Both CABA and NCEL are clinical-stage biotechnology companies, but they operate at very different stages of development and scale.
- CABA commands a substantially larger market capitalization and broader analyst coverage than NCEL, whose trading liquidity is considerably thinner.
- NCEL is at a pre-clinical regulatory stage for its lead candidate, while CABA is advancing a later-stage pipeline with multiple readouts ahead.
- Tickeron AI Verdict: The AI framework currently favors CABA based on its larger market position, deeper liquidity, and more advanced clinical catalysts.
- For deeper context on each name, explore CABA Major News and CABA Today's Price Move, as well as NCEL Major News and NCEL Today's Price Move.
- To see how automated systems are positioning across the market, browse the curated Trending AI Robots page.
Introduction
Investors scanning the biotechnology space often encounter companies with compelling science but sharply different risk profiles. CABA, or Cabaletta Bio, and NCEL, or NewcelX, both pursue potentially transformative cell-based therapies, yet their market positioning, capital bases, and development timelines diverge meaningfully. This stock comparison examines their relative performance, catalysts, and risk factors to help traders and longer-term investors evaluate which profile may better suit current market conditions. Because both names are early-stage and volatile, the analysis emphasizes observable trends, liquidity, and clinical progress rather than speculative outcomes.
CABA Overview and Recent Performance
Cabaletta Bio (CABA) is a clinical-stage biotechnology company developing engineered T-cell therapies, including chimeric antigen receptor T-cell (CAR-T) candidates, for autoimmune diseases. Its lead program, rese-cel (resecabtagene autoleucel), is being evaluated across multiple indications, including myositis and systemic sclerosis. In recent weeks, the company has reported encouraging early clinical and manufacturing data, presented at major medical congresses, and disclosed a 10-year commercial supply agreement with Cellares to automate production of rese-cel.
From a financial standpoint, CABA priced a $150 million underwritten offering with participation from Eli Lilly and other institutional investors, which is seen as strengthening its cash runway. Analyst sentiment has been broadly constructive, with a consensus Buy/Strong Buy posture and price targets well above the recent share price. The stock remains volatile and carries an elevated short-interest ratio, reflecting ongoing debate about single-asset risk and cash burn. Still, its relative performance has outpaced the broader biomedical peer group over the past year.
NCEL Overview and Recent Performance
NewcelX (NCEL) is a regenerative medicine company developing stem-cell-derived therapies, with a lead candidate, NCEL-101, targeting Type 1 diabetes in combination with tegoprubart. Its broader pipeline includes AstroRx for amyotrophic lateral sclerosis (ALS) and a small-molecule platform for sleep and central nervous system disorders. In recent weeks, the company completed a successful Type B pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration, signaling a clearer regulatory path toward first-in-human trials for NCEL-101.
The company has also strengthened its advisory board, secured patents internationally, and raised capital through private placements priced at premiums to the market. However, NCEL operates with a very small market capitalization, limited analyst coverage, and low trading volume, which contributes to pronounced price swings. As a pre-clinical-stage company with modest cash reserves, its investment profile is heavily weighted toward execution and financing risk relative to later-stage peers.
Trending AI Robots
Tickeron maintains hundreds of AI Trading Bots that collectively monitor and trade thousands of individual tickers across varied strategies, timeframes, and performance profiles. Because not every automated system is equally suited to shifting market conditions, Tickeron curates a dedicated Trending AI Robots section featuring only those bots whose approaches are best aligned with the current environment. These systems differ in trading style, holding period, risk tolerance, and the baskets of securities they follow, giving traders a way to compare systematic approaches rather than rely on a single model. Exploring the Trending AI Robots page can offer additional perspective on how automated strategies are positioning across the market.
Head-to-Head Comparison
The most fundamental contrast between the two names is stage of development and scale. CABA is advancing a late-stage cell therapy across multiple autoimmune indications, with a market capitalization in the hundreds of millions of dollars and several active analyst price targets. NCEL is earlier in its journey, with its lead asset yet to enter clinical trials and a market capitalization measured in the tens of millions of dollars.
On momentum, CABA has benefited from a sequence of clinical data disclosures, a large financing, and a strategic manufacturing partnership, supporting improved sentiment despite elevated short interest. NCEL has drawn attention from its regulatory progress and premium-priced financings, but thinner liquidity and limited institutional following amplify its sensitivity to any single headline. In terms of risk, both carry binary, trial-driven outcomes and negative cash flow, but NCEL's smaller capital base and pre-clinical status represent a comparatively higher execution and dilution risk profile.
Tickeron AI Verdict
Based on observable factors such as relative market positioning, liquidity, trend consistency, and the depth of near-term catalysts, Tickeron's AI framework would currently lean toward CABA over NCEL. The preference reflects CABA's larger market capitalization, more established analyst coverage, later-stage pipeline, and a steadier flow of de-risking events, rather than any certainty about clinical outcomes. That said, both names carry substantial risk, and the verdict is best understood as a probabilistic read on current conditions rather than a definitive forecast.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CABA is a Hold and NCEL is a Hold.
CABA's RSI Oscillator ascending out of oversold territory
The RSI Indicator for CABA moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 25 similar instances when the indicator left oversold territory. In 22 of the 25 cases the stock moved higher. This puts the odds of a move higher at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 60 cases where CABA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for CABA just turned positive on October 22, 2026. Looking at past instances where CABA's MACD turned positive, the stock continued to rise in 43 of 49 cases over the following month. The odds of a continued upward trend are 88%.
Following a +17.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where CABA advanced for three days, in 218 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
CABA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CABA as a result. In 76 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CABA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CABA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.047) is normal, around the industry mean (3.498). P/E Ratio (-0.942) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. CABA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CABA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
NCEL's Stochastic Oscillator is sitting in overbought zone for 1 day
Expect a price pull-back in the near future.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 50-day moving average for NCEL moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NCEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
NCEL broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NCEL entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NCEL's RSI Oscillator exited the oversold zone, 33 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on NCEL as a result. In 77 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for NCEL just turned positive on November 03, 2026. Looking at past instances where NCEL's MACD turned positive, the stock continued to rise in 31 of 38 cases over the following month. The odds of a continued upward trend are 82%.
Following a +11.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where NCEL advanced for three days, in 186 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. NCEL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.640) is normal, around the industry mean (3.498). P/E Ratio (4.929) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NCEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CABA | ||
|---|---|---|
OUTLOOK RATING 1..100 | 7 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 51 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 86 | |
P/E GROWTH RATING 1..100 | 9 | |
SEASONALITY SCORE 1..100 | 28 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| CABA | NCEL | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 83% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 84% | 2 days ago 88% |
| MACD ODDS (%) | 2 days ago 88% | 2 days ago 82% |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 84% |
| TrendMonth ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| Advances ODDS (%) | 3 days ago 88% | 22 days ago 84% |
| Declines ODDS (%) | 9 days ago 90% | 3 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 81% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 86% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CABA’s FA Score shows that 1 FA rating(s) are green while NCEL’s FA Score has 0 green FA rating(s).
- CABA’s FA Score: 1 green, 4 red.
- NCEL’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CABA’s TA Score shows that 5 TA indicator(s) are bullish while NCEL’s TA Score has 4 bullish TA indicator(s).
- CABA’s TA Score: 5 bullish, 3 bearish.
- NCEL’s TA Score: 4 bullish, 5 bearish.
Price Growth
CABA (@Biotechnology) experienced а +2.11% price change this week, while NCEL (@Biotechnology) price change was +8.33% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
CABA is expected to report earnings on Mar 18, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CABA and
Correlation & Price change
A.I.dvisor indicates that over the last year, CABA has been loosely correlated with AURA. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CABA jumps, then AURA could also see price increases.
| Ticker / NAME | Correlation To CABA | 1D Price Change % | ||
|---|---|---|---|---|
| CABA | 100% | -3.33% | ||
| AURA - CABA | 49% Loosely correlated | -0.13% | ||
| EDIT - CABA | 49% Loosely correlated | -8.91% | ||
| VIR - CABA | 47% Loosely correlated | -3.63% | ||
| NCEL - CABA | 47% Loosely correlated | +4.00% | ||
| FATE - CABA | 47% Loosely correlated | -8.76% | ||
More | ||||
NCEL and
Correlation & Price change
A.I.dvisor indicates that over the last year, NCEL has been loosely correlated with APVO. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if NCEL jumps, then APVO could also see price increases.
| Ticker / NAME | Correlation To NCEL | 1D Price Change % | ||
|---|---|---|---|---|
| NCEL | 100% | +4.00% | ||
| APVO - NCEL | 63% Loosely correlated | -4.42% | ||
| CANF - NCEL | 62% Loosely correlated | -1.19% | ||
| MLEC - NCEL | 58% Loosely correlated | N/A | ||
| IRON - NCEL | 54% Loosely correlated | +4.16% | ||
| RANI - NCEL | 46% Loosely correlated | -2.47% | ||
More | ||||